Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
By S. Wells, B. Robinson, R. Gagel, H. Dralle, J. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J. Vasselli and 4 more. Journal of Clinical Oncology, 2012
1,374 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/12304b3b7f9386fbf0d71cdb6281d98c8c38d64a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Rita Santos
- Anna Gaulton
- A. P. Bento
- Anne Hersey
- O. Ursu
- C. Bologa
- John P. Overington
- Tudor I. Oprea
Citations in the corpus
- Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Fortunately, vandetanib was approved for patients with unresectable locally advanced or metastatic MTC in 2011 based on moderate clinical results of enhancive median rates of OS and PFS (NCT00410761).(422) Regorafenib is a potent VEGFR-2 inhibitor with pyridine carboxamide derived from sorafenib str”
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, neutral): “Recently, vandetanib has been approved by FDA and EMA for the treatment of patients with locally advanced/ metastatic MTC after therapeutic efficacy has been demonstrated in a phase III trial in patients with advanced MTC [35].”
- A comprehensive map of molecular drug targets (2016, background): “For example, vandetanib, which was approved for the treatment of metastatic medullary thyroid cancer 27 , inhibits the kinase product of the oncogene RET , which is mutated in many patients with medullary thyroid cancer 28 .”
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (2015, neutral): “Twelve percent of patients receiving vandetanib discontinued treatment due to toxicity and 35% required dose reductions because of an adverse event (349).”
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, background): “approval for these cases was based on their documented ability to improve PFS [158, 159].”